CannAssist International Corp. (CNSC) Addresses CBD Absorption Issues with Proprietary CiBiDinol Technology
- CBD products in oil-based form have compromised bioavailability, according to experts
- CNSC’s Xceptol CBD products created with proprietary CiBiDinol technology that addresses absorption issues for superior efficacy
- Third-party Xceptol testing shows 300% increased gut absorption, 400% increased skin penetration when compared to mainstream CBD oil products
Growing in popularity in a myriad of markets, cannabidiol (“CBD”) is a phytocannabinoid that can mimic natural endocannabinoids in the human body for various therapeutic effects. Growing awareness around the use of oil-based CBD has led to skyrocketing popularity among the mainstream public despite bioavailability concerns among healthcare professionals and doctors (https://nnw.fm/6GGZh). CannAssist International (OTCQB: CNSC), a biotechnological pharmaceutical company and owner of Xceptor Labs, has sought to address this issue through its CiBiDinol technology that increases absorbability, bioavailability and shelf life for all CBD products marketed under its Xceptol consumer brand.
Bioavailability – the amount of a substance required to produce a response in the human body – is a growing concern among health professionals and consumers interested in the use of CBD oil for the treatment of various health conditions. Higher bioavailability typically translates to increased effectiveness, leading many CBD users and practitioners to believe that most CBD products’ oil-based nature may reduce absorption because oil and water do not mix.
“Cannabinoids are fat-loving molecules and have to traverse a cellular environment that is aqueous or watery,” said Dr. Patricia Frye, a member of the Society of Cannabis Clinicians. According to Dr. Frye, the effects of oil-based cannabis can be delayed when bioavailability is limited. CNSC’s CiBiDinol technology directly addresses this issue through a proprietary process that combines CBD molecules with penetration-enhancing cyclodextrin, which covers the surface of the molecule rendering it water dispersible.
Marketed under the Xceptol consumer brand, CBD products created using CiBiDinol technology promise increased efficacy, absorption and bioavailability for superior results per dose. Third-party testing confirmed a 300% increase in gut absorption rate and a 400% increase in skin penetration compared to regular oil-based CBD (https://nnw.fm/BDIXY).
CNSC is taking CiBiDinol technology further into mainstream medicine through several regulatory moves, including a submission to the FDA’s bulk drug substance program along with a submission for safety evaluation to the National Science Foundation for Global Recognition. Along with addressing these regulatory issues, the company actively engaged in developing commerce pathways that include state pharmaceutical distribution through State Boards of Pharmacy and offering licensing arrangements for brand-consumer companies.
Established in May 2017, CannAssist, headquartered in San Diego, California, with a management team that includes expert scientists, healthcare professionals and product research specialists. The company’s proprietary CiBiDinol Technology aims to create superior CBD products with higher absorbability, efficacy and longer shelf life. Marketed under the Xceptol brand, CannAssist’s CBD products are sold online through the RangeMe product marketplace and multiple international sales channels throughout Central America, South America, South Africa, the EU, the UK and the Philippines.
For more information, visit the company’s website at www.CannAssistInternational.com.
NOTE TO INVESTORS: The latest news and updates relating to CNSC are available in the company’s newsroom at https://nnw.fm/CNSC
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- CBD products in oil-based form have compromised bioavailability, according to experts
- CNSC’s Xceptol CBD products created with proprietary CiBiDinol technology that addresses absorption issues for superior efficacy
- Third-party Xceptol testing shows 300% increased gut absorption, 400% increased skin penetration when compared to mainstream CBD oil products
Growing in popularity in a myriad of markets, cannabidiol (“CBD”) is a phytocannabinoid that can mimic natural endocannabinoids in the human body for various therapeutic effects. Growing awareness around the use of oil-based CBD has led to skyrocketing popularity among the mainstream public despite bioavailability concerns among healthcare professionals and doctors (https://nnw.fm/6GGZh). CannAssist International (OTCQB: CNSC), a biotechnological pharmaceutical company and owner of Xceptor Labs, has sought to address this issue through its CiBiDinol technology that increases absorbability, bioavailability and shelf life for all CBD products marketed under its Xceptol consumer brand.
Bioavailability – the amount of a substance required to produce a response in the human body – is a growing concern among health professionals and consumers interested in the use of CBD oil for the treatment of various health conditions. Higher bioavailability typically translates to increased effectiveness, leading many CBD users and practitioners to believe that most CBD products’ oil-based nature may reduce absorption because oil and water do not mix.
“Cannabinoids are fat-loving molecules and have to traverse a cellular environment that is aqueous or watery,” said Dr. Patricia Frye, a member of the Society of Cannabis Clinicians. According to Dr. Frye, the effects of oil-based cannabis can be delayed when bioavailability is limited. CNSC’s CiBiDinol technology directly addresses this issue through a proprietary process that combines CBD molecules with penetration-enhancing cyclodextrin, which covers the surface of the molecule rendering it water dispersible.
Marketed under the Xceptol consumer brand, CBD products created using CiBiDinol technology promise increased efficacy, absorption and bioavailability for superior results per dose. Third-party testing confirmed a 300% increase in gut absorption rate and a 400% increase in skin penetration compared to regular oil-based CBD (https://nnw.fm/BDIXY).
CNSC is taking CiBiDinol technology further into mainstream medicine through several regulatory moves, including a submission to the FDA’s bulk drug substance program along with a submission for safety evaluation to the National Science Foundation for Global Recognition. Along with addressing these regulatory issues, the company actively engaged in developing commerce pathways that include state pharmaceutical distribution through State Boards of Pharmacy and offering licensing arrangements for brand-consumer companies.
Established in May 2017, CannAssist, headquartered in San Diego, California, with a management team that includes expert scientists, healthcare professionals and product research specialists. The company’s proprietary CiBiDinol Technology aims to create superior CBD products with higher absorbability, efficacy and longer shelf life. Marketed under the Xceptol brand, CannAssist’s CBD products are sold online through the RangeMe product marketplace and multiple international sales channels throughout Central America, South America, South Africa, the EU, the UK and the Philippines.
For more information, visit the company’s website at www.CannAssistInternational.com.
NOTE TO INVESTORS: The latest news and updates relating to CNSC are available in the company’s newsroom at https://nnw.fm/CNSC
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
